Domenico Maria Mezzapesa

Domenico Maria Mezzapesa

Auto-generated profile, based on publicly available information

Domenico Maria Mezzapesa

Department of Neurology and Stroke Unit, “F. Puca” AOU Consorziale Policlinico

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Sleep Medicine
Verified
Journal Article
Closed access
MMMaria Paola Mogavero
Maria Paola Mogavero
DMDomenico M. Mezzapesa
Domenico M. Mezzapesa
MSMariantonietta Savarese
Mariantonietta Savarese
Lourdes M. DelRossoLourdes M. DelRosso
Lourdes M. DelRosso
Giuseppe LanzaGiuseppe Lanza
Giuseppe Lanza
RFRaffaele Ferri
Raffaele Ferri

1 May 2023 in Stroke
Verified
Journal Article
Closed access
EMEleonora De Matteis
Eleonora De Matteis
FSFederico De Santis
Federico De Santis
RORaffaele Ornello
Raffaele Ornello
BCBruno Censori
Bruno Censori
VPValentina Puglisi
Valentina Puglisi
RGREADAPT Study Group
READAPT Study Group
Background: Randomized controlled trials (RCTs) proved that short-term (21–90 days) dual antiplatelet therapy (DAPT) reduces the risk of early ischemic recurrences after a noncardioembolic minor stroke or high-risk transient ischemic attack (TIA) without substantially increasing the hemorrhagic risk. We aimed at understanding whether and how real-world use of DAPT differs from RCTs. Methods: READAPT (Real-Life Study on Short-Term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or TIA) is a prospective cohort study including >18-year-old patients treated with DAPT after a noncardioembolic minor ischemic stroke or high-risk TIA from 51 Italian centers. The study comprises a 90-day follow-up from symptom onset. In the present work, we reported descriptive statistics of baseline data of patients recruited up to July 31, 2022, and proportions of patients who would have been excluded from RCTs. We compared categorical data through the χ² test. Results: We evaluated 1070 patients, who had 72 (interquartile range, 62–79) years median age, were mostly Caucasian (1045; 97.7%), and were men (711; 66.4%). Among the 726 (67.9%) patients with ischemic stroke, 226 (31.1%) did not meet the RCT inclusion criteria because of National Institutes of Health Stroke Scale score >3 and 50 (6.9%) because of National Institutes of Health Stroke Scale score >5. Among the 344 (32.1%) patients with TIA, 69 (19.7%) did not meet the RCT criteria because of age, blood pressure, clinical features, duration of TIA, presence of diabetes score <4 and 252 (74.7%) because of age, blood pressure, clinical features, duration of TIA, presence of diabetes score 24 hours) DAPT initiation; 776 (72.5%) and 676 (63.2%) patients did not take loading doses of aspirin and clopidogrel, respectively. Overall, 84 (7.8%) patients met the RCT inclusion/exclusion criteria. Conclusions: The real-world use of DAPT is broader than RCTs. Most patients did not meet the RCT criteria because of the severity of ischemic stroke, lower risk of TIA, late DAPT start, or lack of antiplatelet loading dose. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05476081.

2 March 2021 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
EDEugenio Distaso
Eugenio Distaso
GMGiammarco Milella
Giammarco Milella
DMDomenico Maria Mezzapesa
Domenico Maria Mezzapesa
AIAlessandro Introna
Alessandro Introna
EDEustachio D'ERrico
Eustachio D'ERrico
ISIsabella Laura Simone
Isabella Laura Simone
Background: Edaravone was approved as a new treatment for amyotrophic lateral sclerosis (ALS), although there are different opinions on its effectiveness. Magnetic resonance (MRI) measures appear promising as diagnostic and prognostic indicators of disease. However, published studies on MRI using to monitor treatment efficacy in ALS are lacking. Purpose: The objective of this study was to investigate changes in brain MRI measures in patients treated with edaravone. Methods: Thirteen ALS patients assuming edaravone (ALS-EDA) underwent MRI at baseline (T0) and after 6 months (T6) to measure cortical thickness (CT) and fractional anisotropy (FA) of white matter (WM) tracts. MRI data of ALS-EDA were compared at T0 with those of 12 control subjects (CS), and at T6 with those of 11 ALS patients assuming only riluzole (ALS-RIL), extracted from our ALS cohort using a propensity-score-matching. A longitudinal MRI analysis was performed in ALS-EDA between T6 and T0. Results: At T0, ALS-EDA showed a cortical widespread thinning in both hemispheres, particularly in the bilateral precentral gyrus, and a reduction of FA in bilateral corticospinal tracts, in comparison to CS. Thinning in bilateral precentral cortex and significant widespread reduction of FA in several WM tracts were observed in ALS-EDA at T6 compared to T0. At T6, no significant differences in MRI measures of ALS-EDA versus ALS-RIL were found. Conclusions: Patients treated with edaravone showed progression of damage in the motor cortex and several WM tracts, at a six-month follow-up. Moreover, this study showed no evidence of a difference between edaravone and riluzole.

23 March 2023 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
GMGiammarco Milella
Giammarco Milella
AIAlessandro Introna
Alessandro Introna
DMD.M. Mezzapesa
D.M. Mezzapesa
EDE. D’eRrico
E. D’eRrico
AFA. Fraddosio
A. Fraddosio
ISIsabella Laura Simone
Isabella Laura Simone
BACKGROUND AND PURPOSE: The previous studies described phenotype-associated imaging findings in amyotrophic lateral sclerosis (ALS) with a prior categorization of patients based on clinical characteristics. We investigated the natural segregation of patients through a radiologic cluster-based approach without a priori patient categorization using 3 well-known prognostic MR imaging biomarkers in ALS, namely bilateral precentral and paracentral gyrus cortical thickness and medulla oblongata volume. We aimed to identify clinical/prognostic features that are cluster-associated. MATERIALS AND METHODS: Bilateral precentral and paracentral gyri and medulla oblongata volume were calculated using FreeSurfer in 90 patients with amyotrophic lateral sclerosis and 25 healthy controls. A 2-step cluster analysis was performed using precentral and paracentral gyri (averaged pair-wise) and medulla oblongata volume. RESULTS: We identified 3 radiologic clusters: 28 (31%) patients belonged to “cluster-1”; 51 (57%), to “cluster 2”; and 11 (12%), to “cluster 3.” Patients in cluster 1 showed statistically significant cortical thinning of the analyzed cortical areas and lower medulla oblongata volume compared with subjects in cluster 2 and cluster 3, respectively. Patients in cluster 3 exhibited significant cortical thinning of both paracentral and precentral gyri versus those in cluster 2, and this latter cluster showed lower medulla oblongata volume than cluster 3. Patients in cluster 1 were characterized by older age, higher female prevalence, greater disease severity, higher progression rate, and lower survival compared with patients in clusters 2 and 3. CONCLUSIONS: Patients with amyotrophic lateral sclerosis spontaneously segregate according to age and sex-specific patterns of neurodegeneration. Some patients with amyotrophic lateral sclerosis showed an early higher impairment of cortical motor neurons with relative sparing of bulbar motor neurons (cluster 3), while others expressed an opposite pattern (cluster 2). Moreover, 31% of patients showed an early simultaneous impairment of cortical and bulbar motor neurons (cluster 1), and they were characterized by higher disease severity and lower survival.

9 June 2021 in Clinical Drug Investigation
Verified
Journal Article
Closed access
PDF file
FRFederica Rizzo
Federica Rizzo
DMDomenico Maria Mezzapesa
Domenico Maria Mezzapesa
LCLuigi Chiumarulo
Luigi Chiumarulo
MPMosé Parisi
Mosé Parisi
NLNicola Davide Loizzo
Nicola Davide Loizzo
MPMarco Petruzzellis
Marco Petruzzellis

11 January 2024 in medRxiv
Verified
Preprint
Open access
PDF file
EMEleonora De Matteis
Eleonora De Matteis
RORaffaele Ornello
Raffaele Ornello
FSFederico De Santis
Federico De Santis
MFMatteo Foschi
Matteo Foschi
MRMichele Romoli
Michele Romoli
TGthe READAPT Study Group
the READAPT Study Group
Background and purpose: Clinical trials proved the efficacy of short-term dual antiplatelet therapy (DAPT) in secondary prevention of minor ischemic stroke or high-risk transient ischemic attack (TIA). In clinical practice, the use of short-term DAPT is broader than in clinical trials and procedures of clinical trials (i.e. loading dose, timely treatment start) are not always followed. We aimed at evaluating effectiveness and safety of short-term DAPT in real-world. Methods: READAPT (A REAl-life study on short-term Dual Antiplatelet treatment in Patients with ischemic stroke or Transient ischemic attack) ( NCT05476081 ) was an observational multicenter real-world study with a 90-day follow-up. The enrollment closed on 28 th February 2023. We included patients aged 18+ receiving DAPT after minor ischemic stroke or high-risk TIA but no stringent exclusion criteria were applied regarding stroke severity and ABCD 2 score. Primary effectiveness outcome was stroke (ischemic or hemorrhagic) or death due to vascular causes, primary safety outcome was moderate-to-severe bleeding. Key secondary outcomes were the type of ischemic and hemorrhagic events, disability, cause of death, and compliance to treatment. Results: We included 1920 patients; the majority started DAPT after an ischemic stroke (69.9%) rather than a TIA. Primary effectiveness outcome occurred in 3.9% and primary safety outcome in 0.6% of cases. In total, 3.3% cerebrovascular ischemic recurrences occurred, 0.2% intracerebral hemorrhages, and 2.7% bleedings; 0.2% of patients died due to vascular causes. We compared different subgroups of patients and we found significant differences among patients with NIHSS score ≤5 and those without acute lesions at neuroimaging who had higher primary effectiveness outcomes than their counterparts. Additionally, DAPT start after 24 hours from symptom onset was associated with a lower likelihood of bleeding. Conclusions: Short-term DAPT after ischemic stroke or TIA is effective and safe in real-world where a broader population receives the treatment and procedures may differ from clinical trials.